EvaluatePharma - Wyeth - Worldwide

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	16 OCT 2009: Pfizer acquired Wyeth for $68bn ($50.19 per share) in cash & stock. Each outstanding share of Wyeth common stock has been converted into the right to receive $33 in cash (without interest) and 0.985 of a share of Pfizer common stock. Wyeth ceased to trade on NYSE as of date 15 OCT 2009. Wyeth (WYE), was a global provider of healthcare products. Business segments included: Pharmaceuticals, Fort Dodge Animal Health and Consumer Health Care.
Listed or Private Company	Listed
Company Classification	Global Majors
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
8/17/2009	17 Aug: Company announces the redemption of convertible senior debentures, worth $22.6m, which were due on 15 Sept, 2024, to be redeemed at a cash purchase price of $1000 per $1000 principal amount at maturity of the debentures plus any unpaid interest that has accrued from July 15, as part of its acquisition by Pfizer.	63,068	0.5%	334

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Effexor	venlafaxine hydrochloride	Anti-depressants	3,794²	3,928³	+4%
2	Prevnar	pneumococcal vaccine	Vaccines	2,439⁴	2,716⁵	+11%
3	Enbrel	etanercept	Other anti-rheumatics	1,885⁶	2,338⁷	+24%

Note: Shaded Cells⁸

Therapy Area Focus in 2008

Wyeth
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	961
Cardiovascular	0
Central Nervous System	3,994
Gastro-Intestinal	937
Genito-Urinary	1,456
Musculoskeletal	3,332
Oncology & Immunomodulators	608
Respiratory	287
Systemic Anti-Infectives	4,196
Other Rx & OTC Pharma⁹	1,287

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Wyeth ¹⁰	348

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Surprise shortening of NME approval times in recent years (April 13, 2010)

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXXXXXX XXXXXXX (XX XXX XXXX):
XXXXXXX(X) (XXXXXXX XXX XXXXXXX XX) XXXXXXXXX XX XX XXX XXXXXX XXX XXXXXX XXXXXXXXXXXXXX XX XXXXX XXX XXXXXXXXXXXX XXXXXX XXX XX XXXXXXXXX XXXXXXX XX XXXXXXXX XXXXX XXXXXXXX XXXX XXXXX XXXXXXXXXX XXXXXXXX, XXXXXXXXXXX XXXXXXX XXXXXXXX, XXXXXX XXXXXXX XXXXXXXX XXX XXXXX XXXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX X-X:
XXXXX XX XXXXXXX XXX XXXXXXX XX XXXX XX%, XX% XXX XX% XX XXX XXXXXXX XXX XXXX, XXXX XXX XXXX, XXXXXXXXXXXX.

XXXX X-XX:
XX XXXXXXXX XXXX XXXXXXXXXXXXX XX% XX XXXXXXX (XXXXXXXXX XXXXXXX XXXXXXX) XXXXXXXXXXXXX XX XXX XXXXXX XXXXXX XXXX XXXX XXXXXXXXX XX XXXXXXX XXXXXXXX XXXXXXXXX XXXX’X XXXXXX XX XXX XXXXXXX XXXXXXX XX XXXXXX XXXX XXX XXX XXXXXXXXXX XXXXXX XX XXXXX XXXXXXX XXXXXXXX XX XXX-XXXX, XXX XX XXXXXX XXXXXXX XXX XXXXXXXXXXX XXXX XXX XXXXXXXXXXXX XX XXXXXXX XXXXXXXX XX XXXXXXX (XXXXXXXXX XXXXXXX XXXXXXX) XX XXX XXXXXX XXXXXX XXXX XXXXXXXXX XXXXXX XXX XXXXXX XXXXXX XXXXX XX XXXXXXX XX (XXXXXXXX XXXXXXX XXXXXXXX), XXXXXX XX XXXX XXX XXXXXXXXXXX XXX XXXXXXXXXXX XXXXXX XX XXXX.

XXXX XX:
XXXXXX XXXXXXXX XX XXXXXXX XXX XXXXXXX XXX XXXXXXXXX XXX XX XXXXX XXXXXXXXX, XXXXX XXXX XXXXXX, XX XXXX, XX XXXXX XXXXXX

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXXXXXX XXXXXXXXX X% XXX XXX XXXX XXXXXX XXXXXXX XXX XXXXXXXXX X% XXXXXXXXX XXX XXXXXX XX XXXXXXX XXXXXXXX XX XXXXXXXX XXXX XXX XXXX XXXXXX XXXXXXX. XXX X% XXXXXXXX XXXXXXXXX XXX XXXXXX XX XXXXXXX XXXXXXXX XXX XXXXXXXXX XXX XX XXXXX XXXXX XX XXX XXXXXXXX(X) XXXXXX, XXXXXXX(X) XXX XXXXXXXX XXXXXXXXXX XXXXXXXX, XXXXX XXXX XXXXXX XX XXXXXXXXX XX XXXXX'X XXX XXXXXXXXXXXXXX XXXXXXXXXX XXXX XX XXXXXX(X), XXXXXXX(X) XXX XXXXXXXXXXX XXXXXXXX, XX XXXX XX XXXXXXXXX XX XXXXX(X) XXX XXX XXXXXXXX XXXX XX XXXXXXX(XX), XXXXXXX(X) XXX XXXXXXX(XX).

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXXXXXX XXXXXXX (XX XXX XXXX):
XXXXXXX(X), XXXXX'X XXXXXXX XX XXXXXXX XXXXXXXX XXXXXXXXXXXX XXXXXXX XX XXXX XXXXXXX XXX XXXXX XXXXXXXX, XXXXXXXXX XX XX XXX XXXXX'X XXXX-XXXXXXX XXXXXXX. XX XXXXXXX XXXX, XXXXXXX XXXXXX XXX XXXXX XXXXXXX XX XXXXXXX $X.X XXXXXXX XX XXXXXX XXXXXX XXXXX. XXXXXXX XX XXXXXXXXX XX XX XXXXXXXXX XXXXXXXXX XXX XX XXX XXXXXXXX XX XX XXXXXXXX XXXXXXXXXXXX XXXXXXXX (XXXX), XXXX XXX XXXXXXXXXX XXXXXXXXX XXXXXXXXXX XXXXXXXXXX XX XXXXXXXX XXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, X-X:
XXXXX XX XXXXXXX XXXX XX% XXX XX% XX XXX XXXXXXX XXX XXXX XXX XXXX, XXXXXXXXXXXX.

XXXX XX:
XXXXXXX XX XXX XXXXXXX XXX XXXXXXXXXX XXXXXXXX XXXXXXXXXXXX XXXXXXX XX XXXXXXX XXX XXXXX XXXXXXXX XXX XX XXX XXXXXXXXX XX XX XXXXXXXXX XXXXXXXXX XXX XXXXXXXX XX XX XXXXXXXX XXXXXXXXXXXX XXXXXXXX (XXX). XX XXXXXXXX XXX XXXXXXXX XXXX XXXX XX XXXXXXX XXXXX XX XXXXXXX XX XXXX, X XX% XXXXXXXX XXXX XXXX XXXXXXXXXX. XX XXXX, XX XXXX XXXX XXXX XX XXXXXXX XXXXX, XX XXXXXXXX XX XX% XXXX XXXXX XXXX XX XXXX, XXX XX XXXX XXXX XX XXXXXXXXX XX XXXX XXXX XXX XXXXXXX XXXXX XXXXX XXXXXXX XXX XXXXXXXX. XXXXXXX XXXXXX XXX XXXXXXX XX XXXX XXX XXXXXXX XXXXXX XX XXX XXXX XXXX XXXXXX XX XXXX XXXXXXXX XX XXXX (XXXXXXX XXX XXXXXXX) XXX XXX XXXXXXXXXXXX XX XX XXX XXXX XX XXXX (XXXXXXX, XXXXXXXX, XXXXXX, XXXXXXX, XXXXXXX, XXX XXXXXXX, XXXX, XXXXXXXX, XXXXX XXXXXX, XXXXX XXX XXXXXXX).

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXXXXXX XXXXXXXXX X% XXX XXX XXXX XXXXXX XXXXXXX XXX XXXXXXXXX X% XXXXXXXXX XXX XXXXXX XX XXXXXXX XXXXXXXX XX XXXXXXXX XXXX XXX XXXX XXXXXX XXXXXXX. XXX X% XXXXXXXX XXXXXXXXX XXX XXXXXX XX XXXXXXX XXXXXXXX XXX XXXXXXXXX XXX XX XXXXX XXXXX XX XXX XXXXXXXX(X) XXXXXX, XXXXXXX(X) XXX XXXXXXXX XXXXXXXXXX XXXXXXXX, XXXXX XXXX XXXXXX XX XXXXXXXXX XX XXXXX'X XXX XXXXXXXXXXXXXX XXXXXXXXXX XXXX XX XXXXXX(X), XXXXXXX(X) XXX XXXXXXXXXXX XXXXXXXX, XX XXXX XX XXXXXXXXX XX XXXXX(X) XXX XXX XXXXXXXX XXXX XX XXXXXXX(XX), XXXXXXX(X) XXX XXXXXXX(XX).

XXXXXXXX XX $X:
X) +XXXX.XXX XXXXX XXXXXXXXX XX XXXXX
X) -XXX.XXX XXXXX XXXXXXXXX XX XXXXXX XXX XX XXXX (XXX XXXX - XXX XXXX).XXXXXX XXXXXXXXX XXXXX XX ¥XXXXXX XXXX $X = ¥XXX.XXXXXXXXXXX.

XXXXXXX XXXXXXX:

XXXXX XXXXXXX XX XXXXXXXXXXXXXX XXXX XXXX XXXXXXX XXX% XX XXXXXXXX XXXXX XX XXXXX XXXXXXXXXXXXX XXXXXXX XXXX.

XXXXXX: XXXX XX-X, XXXX X-XX:
XXXXXX , XXXXXXXXX XXX XXXXXXXX XXXXXXX XXXXXXXXXX XXXX X XX-XXXXXXXXX XXXXXXXXXXX XXXX XXXXX, XXXXX XXXXXXXXX XXXXXXXXXXXXX XX% XX XXX XXX XXXXXXX XX XXXX.

XXXX XX:
XXXXXXXXXXXXX XXXXXXXXXXXXXXX XXX XXXXXXX XXXXXXXXX XX% XX XXXX XXX XXXXXXXXX XX% XXXXXXXXX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX. XXX XX% XXXXXXXX XXXXXXXXX XXX XXXXXX XX XXXXXXX XXXXXXXX XXX XXX XXXXXXXXX XX XXXXXX XXXXX XX XXXXXX XXXXXXXXX XXXX XXXXXX XXXXXXXXX.

XXXXXX: XXXXX XXXX XX-X, XXXX X-X:
XX XXXXX XX, XXXX, XX XXX XXXXX XXXXXXXXXXXXXXX, X XXXXXXXX XX XXXXX, XXXXXXXXX XXXXXXX XX XXX XXX XXXXXXXX XXXXXXXX XXX XXXXXX, XX XXXXX XXX X.X. XX XXX XXXXXXXX X XXXXX XXXXXXX XXXXXXXX XX XXX XXXX XX XXXXXXXXXX, XXXXXXXXX XXXXXXXXXXXX. XXXX XXXXXXXXXXX XX XXX XXXXX XXXXXXX XXXXXXXX XXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXXX XXX XXXXXXXXXX XXXXXXXX XXX XXXXXXXXXXXX, XXXXXXXXX XXXXXXXX XXX XXXXXX XXXXXXXX XXX XXXXXX XXXXXXXXXXXX XXXXXXXXX. XX XXXX XX XXXX XXXXXXXX XXXXXX, XXX XXX XXXX XXXXXXXX XXX XXXXXXXXXXXXXX XX X XXXX XXX XXXXXX XX XXX XXXX XX X XXXXXXXXXX XXXXX. XXXXXXXXXXXX, XXXXXXXXX XXX XXX XXX-XXXXX XX XXXXXXXXX X, XXXX XXXXXXXXX XXXXX XXXXXX XX XXXXXXXXXXXXXX XXX XXXXX XXXXXXXXXXXXX XXXXXX XXXXXXXXXX XX XXXXXXXX XXXXXXX XXXX XXX-XXXXXXXX, XXX XXX XXXXXXXXX XXXX XXX XXXXX XXXXXXX XXX XXXXXXXX XXXXXXXX XX XXX X.X. XX XXX XXX XXXXXXXXXX XXXXX XXX XXXXXX (XXX XXXXX XXX-XXXXXXXX) XX XXXXXXXXXXXX XX XXXXXXX XXX XXXX XX XXXXXXXXXXXX XXXXXXXXXXXXXX XXX XXXXX XXXXXXXX XXXXXX XXXXXXXXXX XXXX XXX XXXX XX XXXXXXXXXX XXXXXX XXXXXXXXX XXX XXXXXXXXX. XXX XXX XXXX XXXXXXXXX XXXX XXX XXXXXXXX XXXX XXX XXXXXX XX XXXXXXXX XXXX X XXXXXXXXXXXXX XXXX XX XXXXXXXXXX XXXXXXXXX XXXXXXXXX XXX XXXX XX XXXXXXXXXXXX XXXXXX XXXXXXXXXX. XX XXXXXXXX XXXX, XX XXXXXX XXXX XXX XXX XX XXX XXXXXXXX XXXXXXXXX XX XXX X.X. XX, XXX XX XXXXXXXX XX XXXX XXXX XXX XXX XX XXXXXXXX XXX XXXXXXXXX XXXXXXX XX XXX XXXXXX XXXX.

XX XXXXXXXX, XXXXX XXX XXXXXXX XXXXX XXXXXXXXXXX XXXXXXXXXX XXXXXXX XXXX XXX XXXX XXXXXXXXXX XXXXXX XXXXXX XXXXXX XXXXXXX XXXXX. XXX XXXXXXX, XX XXXX X, XXXX, XXX XXX XXXXXX XX XXXXX XXXXXXXXXXXXX XXXXXXXXX XX XXXXXXX XXXXXX XXXXXX XX XXX-XXXXXXXX XXX XXX XXXXXXXX XXXXXXXXXXX XXXXXXX XXX XXX XX XXXXX XXXXXXXXX XXX XXX
XXXXXXXXXXX XX XXXXXXXX XXX XXXXX XXXXXXX XX XXXXXXXX XXX XXXXX XXXXXX XXX XXXXXX XXXX XX XXX XXXXXXX XX XXXXXXX XXXXXXX XXXXXXXX XX XXXXXXXX XXX XXXX XXX XXXXXXXX XX XXX-XXXXXXXX XX XXXXXXXXX XXXXXXXX. XXXXXXXXXXX, XXXXXXXXX XXX XXXX XX, XXXX XXXXXXXXXXXX XXX XXXXXXXXXX XXXXX XXXXXXXX XXXXXXXXX (“XXXXX”) XXXXXXX, XX XXXX XX, XXXX, XX XXXXXXXX XXXXXXXXXXXX XXXX XXX XXX XXXXXXX X XXXXXXXX XXXXXXXX XXXXXX XXXX XXXX XXXXX XXXX XXXXXXXXXX XXXXXXXXXXX XXXX XX XXXXXXXXX XXX XXX XX XXXXXX XX XXXXXXXXX XXXXXXXX XXXX XXXXXXX XXXXXXXX XX XXXXXX XXXXXX XXXXXXXXX. XX XXXXXXXX XX XXXX XXXX XXX XXX XX XXXXXXX XX XXXX XXX XXXXX-XXXXX XXXXXXXXX XXXXXXXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXXXXXX XXXXXXXXX X% XXX XXX XXXX XXXXXX XXXXXXX XXX XXXXXXXXX X% XXXXXXXXX XXX XXXXXX XX XXXXXXX XXXXXXXX XX XXXXXXXX XXXX XXX XXXX XXXXXX XXXXXXX. XXX X% XXXXXXXX XXXXXXXXX XXX XXXXXX XX XXXXXXX XXXXXXXX XXX XXXXXXXXX XXX XX XXXXX XXXXX XX XXX XXXXXXXX(X) XXXXXX, XXXXXXX(X) XXX XXXXXXXX XXXXXXXXXX XXXXXXXX, XXXXX XXXX XXXXXX XX XXXXXXXXX XX XXXXX'X XXX XXXXXXXXXXXXXX XXXXXXXXXX XXXX XX XXXXXX(X), XXXXXXX(X) XXX XXXXXXXXXXX XXXXXXXX, XX XXXX XX XXXXXXXXX XX XXXXX(X) XXX XXX XXXXXXXX XXXX XX XXXXXXX(XX), XXXXXXX(X) XXX XXXXXXX(XX).

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NameIncludes: Immunex (100% until 2000)